Intern Med. 2013;52(10):1049-53.

Maintenance of the remission stage of Crohn’s disease with adalimumab therapy during pregnancy.

Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T.

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan. tmizoshi@med.nagoya-cu.ac.jp

 

Abstract

A 25-year-old pregnant woman complained of abdominal pain and diarrhea. Total colonoscopy provided a diagnosis of Crohn’s disease (CD) of the large intestine (Crohn’s colitis). Because the patient was allergic to mesalazine, adalimumab (ADA) was used as maintenance therapy during pregnancy, following prednisolone as remission induction therapy. Remission of the patient’s CD was maintained with ADA, and the patient delivered a baby girl without any difficulties. Remission of the patient’s CD continued to be maintained with the administration of ADA after childbirth. We believe that this is the first report of the use of ADA therapy in a pregnant CD patient in Japan.

Regarding to the therapy during pregnancy in Crohn’s disease (CD), there is little evidence.  We consider that adalimumab (ADA), a pregnancy category B drug, is an optional therapy for the maintenance of the remission stage in CD during pregnancy.

PMID: 23676589

 

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann